Filing summary
Entity and period: The supplied metadata names KORU Medical Systems, Inc., but this filing identifies the registrant as Repro Med Systems, Inc. (also referred to as RMS Medical Products). It is an annual Form 10-K for the fiscal year ended February 29, 2016, compared with the year ended February 28, 2015—not a quarterly filing. The company designs and manufactures ambulatory infusion and emergency medical devices, led by its FREEDOM60 infusion system and related products.
Financial performance and liquidity
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Net sales | $12.25 million | $11.24 million | +8.9% |
| Gross profit / margin | $7.60 million / 62.1% | $6.69 million / 59.5% | Margin +2.6 percentage points |
| Operating profit / margin | $1.18 million / 9.6% | $1.15 million / 10.2% | Profit +3.0% |
| Net income / margin | $0.78 million / 6.4% | $0.75 million / 6.7% | +3.9% |
| Operating cash flow | $1.91 million | $0.83 million | +$1.09 million |
| Cash and cash equivalents | $4.20 million | $2.56 million | +$1.64 million |
Domestic sales rose 12.2% to $10.20 million; international sales declined 4.8% to $2.05 million. Management attributed international weakness to currency translation, a prior-year customer’s temporary treatments, and a temporary customer loss, partly offset by new accounts. Infusion products drove growth. Gross-margin improvement reflected lean manufacturing, higher capacity, and lower assembly labor costs, partly offset by an accrual for a voluntary market withdrawal related to third-party packaging defects.
Operating expenses increased 16.0% to $6.42 million: SG&A rose 24.1% to $5.94 million, while R&D fell 55.7% to $0.21 million. SG&A increases included patent litigation and regulatory consulting costs, reorganization-related salary, severance, recruiting and consulting costs, trade-show spending, and director compensation.
At year-end, current assets were $7.12 million and current liabilities were $1.11 million (approximately 6.4x current coverage). Cash plus certificates of deposit totaled $4.46 million; inventory was $1.04 million and accounts receivable $1.35 million. Total liabilities were $1.28 million. The balance sheet reports no interest-bearing borrowings. Operating cash flow improved partly through lower receivables and inventory and higher payables/accruals; investing used $0.19 million, primarily for equipment, tooling, and patents, and financing used $0.08 million, primarily for share repurchases. Management said available cash and expected operating cash flows should fund operations, R&D, and capital spending for the next 12 months.
Material changes, outlook, and risks
- Business and outlook: RMS introduced the smaller FreedomEdge pump in March 2015. Management expects continued growth in subcutaneous immunoglobulin and sees potential in antibiotics, chemotherapy, and pain applications, as well as international expansion. It provided no quantified revenue or earnings guidance and cautioned that product development may not yield commercial success.
- Customer concentration: One distributor generated approximately 55.3% of gross product revenue, up from 52.9% in FY2015. Receivables from that customer were $0.5 million at year-end, versus $1.0 million a year earlier.
- Regulatory issue: An FDA inspection in June 2015 followed a trade complaint and resulted in a Form 483. The company received an FDA Warning Letter on February 29, 2016, responded on March 18, and said it was working with the FDA to address the findings; closure could take at least six months. Management described the letter as advisory, while noting ongoing agency engagement.
- Litigation and contingency: Patent and unfair-business-practice litigation with EMED Technologies is ongoing. A 2015 preliminary injunction restricts certain company statements; EMED sought another injunction concerning California sales in March 2016. The company disputes EMED’s patents and obtained USPTO review proceedings, but litigation outcomes are uncertain. Separately, former litigation counsel verbally waived approximately $0.5 million of unpaid invoices after withdrawing in March 2016; the company reversed the fees and said it did not expect collection. Verify the accounting treatment and any subsequent developments.
- Other risks and unusual items: Raw-material price increases may not be recoverable through pricing; reimbursement policy, competition, FDA compliance, and reliance on key personnel are risks. Cash at multiple banks exceeded FDIC insurance limits. The company repurchased 180,406 shares for an average $0.45 under a program authorizing up to 1 million shares, and granted 1.06 million stock options outstanding at year-end. The company expects the new lease accounting standard to materially affect its financial condition and results upon adoption.
- Governance and controls: Cyril Narishkin became President in April 2016, replacing Andrew Sealfon, who remained CEO. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal control. The financial statements received an unqualified audit opinion.
Investor verification priorities
- Confirm the registrant’s identity and relationship to the KORU Medical Systems name in the request.
- Review FDA Warning Letter findings, remediation milestones, and whether the agency has closed the matter.
- Track EMED litigation, potential restrictions on California sales, and the treatment or collectability of the waived $0.5 million legal invoices.
- Assess dependence on the distributor responsible for 55.3% of gross product revenue and the durability of domestic growth amid declining international sales.
- Reconcile improved operating cash flow with working-capital movements, and monitor liquidity, uninsured cash, and capital allocation under the repurchase program.
- Evaluate the commercial uptake of FreedomEdge and expansion into new therapies and international markets against management’s unquantified growth expectations.